Showing results (161-170 of 206) with videos related to
Sort By:
Pageof 21
Blood|July 30, 2025
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid MalignanciesTraci L Kruer, Ariel Quintana-Gonzalez, Hannah L Newman, et al.Blood|July 31, 2020
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotypeDavid A Sallman, Amy F McLemore, Amy L Aldrich, et al.Blood Advances|August 8, 2023
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapiesEdward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMMLChristopher T Letson, Maria E Balasis, Hannah Newman, et al.Blood|June 4, 2017
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMMLAkihide Yoshimi, Maria E Balasis, Alexis Vedder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic SyndromesDavid A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.Blood Advances|March 22, 2023
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditionsAmy E DeZern, Johannes B Goll, R Coleman Lindsley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic SyndromesAziz Nazha, Rami Komrokji, Manja Meggendorfer, et al.Blood|March 10, 2021
Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMMLMargaux Sevin, Franck Debeurme, Lucie Laplane, et al.Journal of the American Heart Association|May 6, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid LeukemiaSruthi Selvakumar, Sanath Shetty, Alexis Behne Sharma, et al.Pageof 21